



Instruction guide: IAS Knowledge Toolkits

This instruction guide provides an overview of how to navigate the IAS Knowledge Toolkits. The International AIDS Society (IAS) developed these toolkits as part of a core goal of investing in the HIV workforce by building the skills and knowledge that are needed to end the epidemic.

The full package offers four downloadable toolkits created exclusively for IAS Members to access and best utilize the key science and research presented at the International AIDS Conferences and IAS Conferences on HIV Science.

WHAT'S INCLUDED



Click on the link of the scientific track on the web page to automatically download each toolkit by topic area. Each individual package includes the PowerPoint presentation for that track and a PDF with the corresponding speaker notes in a single zipped folder.

NAVIGATION

Once downloaded, the presentations have been designed to enable quick navigation to specific topic areas, studies, populations and more.



The 'Overview' slide (slide three in all sets) includes buttons that link to specific topics within the presentation. Please note that all functions must be executed from the SLIDE SHOW mode. To return to the 'Overview' slide, click on the IAS logo in the top left corner of any slide. See example below.








REFERENCES AND SOURCES

The references provided in the bottom right corner of each slide links to the relevant sources from the conference (e.g. abstract summaries, presentation slides, or video recordings). See example below.


Progress on Vaccines

 **The Antibody Mediated Prevention (AMP) Studies**

- VRC01: Broadly neutralising antibody prevented infection in animal models
 - Safe and well tolerated during three Phase I trials with 140 human participants
- Can a passively infused monoclonal antibody prevent HIV-1 infection in high risk adults?
- Two placebo controlled trials opened earlier in 2016

	HVTN 704/HPTN 085	HVTN 703/HPTN 081	
2,700 MSM & TG			1,500 Women

- Powered to detect 60% efficacy; and to associate VRC01 plasma level with protection
- Variation in the doses may define the optimal concentrations of neutralizing activity associated with protection from acquisition in two cohorts with different routes of acquisition/genital tract immunology


Mgodli TUSY0305 Corey WEPL0104

CONTACT

Please contact IAS Member Services, at memberservice@iasociety.org with any questions or feedback.